MAIA Biotechnology Files 8-K: Material Agreement & Equity Sales
Ticker: MAIA · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1878313
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
MAIA Bio inked a big deal and sold some stock, filing an 8-K on 12/16/25.
AI Summary
On December 16, 2025, MAIA Biotechnology, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing is a current report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Why It Matters
This 8-K filing indicates significant corporate activity for MAIA Biotechnology, Inc., including a material definitive agreement and potential equity transactions, which could impact its financial standing and stock performance.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial and regulatory risks.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- December 16, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41455 (commission_file_number) — SEC File Number
- 444 West Lake Street, Suite 1700 (address) — Principal executive offices
- Chicago, IL 60606 (address) — Principal executive offices
- (312) 416-8592 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by MAIA Biotechnology, Inc. on December 16, 2025?
The filing states that MAIA Biotechnology, Inc. entered into a material definitive agreement on December 16, 2025, but the specific details of this agreement are not provided in the excerpt.
What type of equity securities were sold by MAIA Biotechnology, Inc. under unregistered sales?
The filing mentions unregistered sales of equity securities, but the specific type and details of these securities are not disclosed in the provided text.
What are the principal executive offices of MAIA Biotechnology, Inc.?
The principal executive offices of MAIA Biotechnology, Inc. are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
What is the SEC file number for MAIA Biotechnology, Inc.?
The SEC file number for MAIA Biotechnology, Inc. is 001-41455.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is December 16, 2025.
Filing Stats: 1,331 words · 5 min read · ~4 pages · Grade level 13.1 · Accepted 2025-12-16 21:57:10
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (" Common Stock "), and (ii)
- $1 — a purchase price per Investor Share of $1.224, for an aggregate purchase price of
- $1,289,792 — gregate purchase price of approximately $1,289,792. The Investor Warrants are exercisabl
- $1.224 — a purchase price per Director Share of $1.224 for an aggregate purchase price of appr
- $219,998 — gregate purchase price of approximately $219,998. The Director Warrants are exercisable
- $100,000 — gregate purchase price of approximately $100,000. Company director Stan Smith subscribed
- $70,000 — gregate purchase price of approximately $70,000. Company director Steven Chaouki subscr
- $50,000 — gregate purchase price of approximately $50,000 The Shares and the Warrants (and the
- $2,253,896 — ements are expected to be approximately $2,253,896, prior to deducting offering expenses p
Filing Documents
- form8-k.htm (8-K) — 53KB
- ex4-1.htm (EX-4.1) — 104KB
- ex4-2.htm (EX-4.2) — 95KB
- ex10-1.htm (EX-10.1) — 533KB
- ex99-1.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 15KB
- 0001493152-25-028041.txt ( ) — 1144KB
- maia-20251216.xsd (EX-101.SCH) — 3KB
- maia-20251216_lab.xml (EX-101.LAB) — 33KB
- maia-20251216_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 16, 2025 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 4